Myriad Genetics Inc (MYGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Myriad Genetics Inc (MYGN) has a cash flow conversion efficiency ratio of 0.029x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($10.60 Million) by net assets ($368.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Myriad Genetics Inc - Cash Flow Conversion Efficiency Trend (1995–2025)
This chart illustrates how Myriad Genetics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Myriad Genetics Inc (MYGN) financial obligations for a breakdown of total debt and financial obligations.
Myriad Genetics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Myriad Genetics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
RDC Semiconductor Co Ltd
TWO:3228
|
-0.019x |
|
Guangxi Fenglin Wood Industry Group Co Ltd
SHG:601996
|
0.039x |
|
Changshu Tongrun Auto
SHG:603201
|
N/A |
|
Hey-Song Corp
TW:1234
|
-0.001x |
|
JMT Network Services Public Company Limited
BK:JMT
|
0.024x |
|
Hangzhou Zongheng Commun
SHG:603602
|
-0.104x |
|
Charming Medical Limited Class A Ordinary Shares
NASDAQ:MCTA
|
N/A |
|
Aces Electronics Co Ltd
TW:3605
|
0.035x |
Annual Cash Flow Conversion Efficiency for Myriad Genetics Inc (1995–2025)
The table below shows the annual cash flow conversion efficiency of Myriad Genetics Inc from 1995 to 2025. For the full company profile with market capitalisation and key ratios, see Myriad Genetics Inc (MYGN) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $368.00 Million | $1.80 Million | 0.005x | +139.42% |
| 2024-12-31 | $701.10 Million | $-8.70 Million | -0.012x | +91.24% |
| 2023-12-31 | $783.20 Million | $-110.90 Million | -0.142x | -17.99% |
| 2022-12-31 | $885.80 Million | $-106.30 Million | -0.120x | -724.41% |
| 2021-12-31 | $967.80 Million | $18.60 Million | 0.019x | -79.77% |
| 2020-12-31 | $881.00 Million | $83.70 Million | 0.095x | +23.60% |
| 2019-12-31 | $1.09 Billion | $83.70 Million | 0.077x | -36.01% |
| 2018-12-31 | $964.90 Million | $115.90 Million | 0.120x | -12.03% |
| 2017-12-31 | $777.80 Million | $106.20 Million | 0.137x | -38.58% |
| 2016-12-31 | $748.10 Million | $166.30 Million | 0.222x | +4.76% |
| 2015-12-31 | $662.10 Million | $140.50 Million | 0.212x | -19.78% |
| 2014-12-31 | $719.00 Million | $190.20 Million | 0.265x | +10.83% |
| 2013-12-31 | $728.59 Million | $173.90 Million | 0.239x | +6.99% |
| 2012-12-31 | $635.66 Million | $141.80 Million | 0.223x | -3.35% |
| 2011-12-31 | $566.79 Million | $130.83 Million | 0.231x | -17.01% |
| 2010-12-31 | $557.58 Million | $155.09 Million | 0.278x | +43.71% |
| 2009-12-31 | $434.22 Million | $84.04 Million | 0.194x | -20.58% |
| 2008-12-31 | $425.65 Million | $103.74 Million | 0.244x | +420.88% |
| 2007-12-31 | $340.36 Million | $-25.85 Million | -0.076x | +32.31% |
| 2006-12-31 | $249.78 Million | $-28.03 Million | -0.112x | +34.67% |
| 2005-12-31 | $135.67 Million | $-23.30 Million | -0.172x | +3.62% |
| 2004-12-31 | $173.28 Million | $-30.88 Million | -0.178x | +37.40% |
| 2003-12-31 | $163.49 Million | $-46.54 Million | -0.285x | -124.90% |
| 2002-12-31 | $128.87 Million | $-16.31 Million | -0.127x | -367.92% |
| 2001-12-31 | $139.56 Million | $-3.78 Million | -0.027x | -112.25% |
| 2000-12-31 | $77.71 Million | $17.16 Million | 0.221x | +175.51% |
| 1999-12-31 | $48.20 Million | $-14.10 Million | -0.293x | -140.29% |
| 1998-12-31 | $57.50 Million | $-7.00 Million | -0.122x | -22.11% |
| 1997-12-31 | $66.20 Million | $-6.60 Million | -0.100x | -599.91% |
| 1995-12-31 | $70.20 Million | $1.40 Million | 0.020x | -- |
About Myriad Genetics Inc
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovar… Read more